TrialJapanese journal of clinical oncology2019

Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130).

Hiroji Iwata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.